Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Let's say you're reading a story, or playing a game of chess. You may not have noticed, but each step of the way, your mind ...